Study Finds CBD Isolates Overcome Clinical Efficacy Limitations of CBD Oil Extracts
Cannabidiol (CBD) isolates are suddenly getting a lot of attention in the scientific and medical communities and rave reviews by patients.
By now, most people are familiar with CBD extracts, which typically come in the form of an oral concentrate taken under the tongue.
Most CBD extracts on the market today contain up to 113 different cannabinoids plus other plant materials such as oils and other phytonutrients, known as ‘full-spectrum’ or ‘broad-spectrum.’
What sets CBD Isolate apart?
The additional purification processes they undergo to essentially “isolate” the CBD molecules in their purest form.
CBD isolate is a dry, crystalline form of CBD, purified to the extent that up to 99 percent of the oil and additional plant nutrients are removed.
CBD is Proving To Be an Effective Treatment for Many Ailments
While CBD is proving to be an effective treatment for many ailments, there are limitations on the immediacy and duration of its effectiveness, even at high doses, according to authors of a 2015 Israeli study.
The study, which charted efficacy over a 24-hour period, found:
- Full-spectrum results follow a bell-shaped curve peaking at a 6-hour mark, regardless of the size of the dose.
- Isolated CBD were more consistently effective over time and higher doses improved efficacy.
Highlights of Israeli Study
Abstract: Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti‐in‐ flammatory and anti‐anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell‐shaped dose‐response was observed, which limits its clinical use. In the present study, they have studied the anti‐inflammatory and anti‐nociceptive activities of standardized plant extracts derived from the Cannabis sativa L., clone 202, which is highly enriched in CBD and hardly contains any psychoactive ingredients. In stark contrast to purified CBD, the clone 202 extract, when given either intraperitoneally or orally, provided a clear correlation between the anti‐inflammatory and anti‐nociceptive responses and the dose, with increasing responses upon increasing doses, which makes this plant medicine ideal for clinical uses. The clone 202 extract reduced zymosan‐induced paw swelling and pain in mice, and prevented TNFα production in vivo. It is likely that other components in the extract synergize with CBD to achieve the desired anti‐inflammatory action that may contribute to overcoming the bell‐shaped dose‐response of purified CBD. We therefore propose that Cannabis clone 202 (Avi‐ dekel) extract is superior over CBD for the treatment of inflammatory conditions.
Citation: Gallily, R., Yekhtin, Z. and Hanuš, L.O. (2015) Overcoming the Bell‐Shaped Dose‐Response of Can‐ nabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology & Pharmacy, 6, 75‐85. http://dx.doi.org/10.4236/pp.2015.62010